EXAMINE: targeting risk and treatment in diabetes

Affiliations

¹ Medical University Vienna, Anaesthesia and Intensive Care, Vienna, Austria.
² Medical University Vienna, Anaesthesia and Intensive Care, Vienna, Austria. Electronic address: stephanie.neuhold@meduniwien.ac.at.

Comment

Martin Hülsmann et al. Lancet. 2015.

. 2015 Oct 10;386(10002):1444-5.

doi: 10.1016/S0140-6736(15)00407-9.

¹ Medical University Vienna, Anaesthesia and Intensive Care, Vienna, Austria.
² Medical University Vienna, Anaesthesia and Intensive Care, Vienna, Austria. Electronic address: stephanie.neuhold@meduniwien.ac.at.

No abstract available

Comment in

EXAMINE: targeting risk and treatment in diabetes - Authors' reply.
White WB, Kupfer S, Zannad F. White WB, et al. Lancet. 2015 Oct 10;386(10002):1445. doi: 10.1016/S0140-6736(15)00408-0. Lancet. 2015. PMID: 26466044 No abstract available.

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB; EXAMINE Investigators. Zannad F, et al. Lancet. 2015 May 23;385(9982):2067-76. doi: 10.1016/S0140-6736(14)62225-X. Epub 2015 Mar 10. Lancet. 2015. PMID: 25765696 Clinical Trial.